Amgen’s Marc de Garidel elected EBE president
pharmafile | July 14, 2010 | Appointment | Research and Development | Amgen, European Biopharmaceutical Enterprises, appointment, research and development
Brussels-based industry association the European Biopharmaceutical Enterprises has elected Amgen’s Marc de Garidel as its new president.
He will serve for a two-year term and takes over the post from Genzyme’s senior vice president of global market access Dr Carlo Incerti, who will continue to sit on the EBE board as vice president
Mr de Garidel is vice president south region of Amgen International, based in Zug, Switzerland and has served on the EBE board as vice president and treasurer since April 2006.
Commenting on his election, Mr de Garidel said he was eager to further drive the development of EBE as a strong voice for biopharmaceuticals in Europe.
The EBE has also elected a number of other industry executives to its board of directors including: Dr Roberto Gradnik (executive VP, Merck Serono), Dr Edwin Moses (chairman and chief executive of Ablynx), Søren Tulstrup (president and chief executive of Santaris Pharma), Dr Ralf Schumacher (head of biologics research at Roche) and Dr Ignacio Faus (chief executive of Palau Pharma).
Related Content

PlasmidFactory founder Dr. Martin Schleef honoured with the NRW Innovation Award 2025
The founder and long-standing CEO of PlasmidFactory, Dr. Martin Schleef, was honoured in Düsseldorf with …

AAX Biotech announces collaboration for cardiovascular antibody therapy
Swedish biotech firm AAX Biotech has entered a new collaboration focused on the development of …

Research finds tablet effective in slowing progression of Alzheimer’s disease over 18 months
TauRx Pharmaceutics reports that hydromethylthionine mesylate (HMTM) could be an oral treatment for slowing the …






